Tasheda Navarro

Tasheda Navarro is Vice President of Clinical Operations of Vincerx. Before joining Vincerx, Ms Navarro was the senior director of clinical operations of Acerta Pharma from March 2014 to August 2020. Ms Navarro led the clinical operations department as well as the global chronic lymphocytic leukemia (CLL) program for CALQUENCE®, which was one of the fastest joint approvals in US, Canada, and Australia. Before that, Ms Navarro was the lead clinical trial manager of a global phase 3 trial of a novel immuno-oncology prostate cancer drug at Bavarian Nordic from April 2012 to March 2014. Before that, Ms Navarro worked at Pharmacyclics LLC from March 2010 to March 2012 as the senior clinical trial manager who managed the ibrutinib phase 2 trial in CLL that lead to an accelerated approval in CLL in 2014. Tasheda has also worked on various hematology and oncology programs at Astex, Amgen, and Genentech.

Tasheda graduated with a BS in Cell and Molecular Biology from University of Washington in Seattle.